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ABSTRACT
Objective: We aim to assess the bone mineral density (BMD) and bone biochemical parameters in Iraqi patients with β-thalassemia major (β-TM).
Methods: Dual-energy X-ray absorptiometry scan was used to evaluate bone density and interpreted about Z-score which compares to the BMD of 
age-, sex-, and ethnicity-matched reference population. Biochemical parameters such as calcium, 25-OH Vitamin D, parathyroid hormone, and serum 
ferritin (SF) evaluated.
Results: No statistical difference in SF between pediatrics and adults was determined; however, 66 patients were having their SF between 1000 and 
2500 ng/ml and 122 patients with SF ˃2500 ng/ml. Calcium and Vitamin D levels are low in both adults and pediatrics. The bone status shows high 
percentages of osteoporosis 62% and 54.5% for pediatrics and adults, respectively, as well as osteopenia 27% and 34.3% for both pediatric and adults 
and to a lesser extent normal bone status 11% for each.
Conclusion: Osteopathy has a high prevalence in Iraqi patients with β-TM and should receive an optimal transfusion and chelation therapy to prevent 
bone expansion. Calcium and Vitamin D should be routinely determined to prevent deficiency.
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INTRODUCTION
Beta-thalassemia syndrome is a group of Hereditary Blood Disorders 
that are mainly characterized by the reduction or absence of beta-
globin chain synthesis, resulting in a reduction of hemoglobin in red 
blood cells (RBCs), decreased the production of RBCs and consequently 
anemia [1,2]. Beta-thalassemia usually inherited as an autosomal 
recessive disease, more than 200 β-thalassemia mutations have been 
identified, in some of which severe anemia is produced [3]. In Iraq, there 
is a high prevalence of β-thalassemia major (β-TM) (the prevalence rate 
in 2015 was 27.4/100,000 populations) [4]. β-TM refers to a severe 
phenotype which occurs when patients are homozygous or compounds 
heterozygous for β chain mutation (β+/β0, β0/β0), patients commonly 
present with symptoms within the first 2 years of life [5,6]. The 
cornerstone management for patients with β-TM is based on lifelong 
transfusion and iron chelation [7]. Transfusion aims to correct anemia, 
suppress ineffective erythropoiesis and to inhibit gastrointestinal iron 
absorption [8]. Normally humans have no mechanism for excreting 
excess iron in iron overload conditions [9].
Physiologically two distinct cell types are in charge of the maintenance 
and renewal of the bone: The osteoblasts which are responsible for bone 
formation and the osteoclasts which are responsible for bone resorption 
and remodeling [10]. The essential pathway that links osteoclast-mediated 
bone resorption with osteoblast-mediated bone formation consists of a 
paracrine system that comprises receptor activator of nuclear factor-κB 
ligand (RANKL), its RANK, and soluble protein osteoprotegerin (OPG). 
RANKL produced by osteoblasts and their precursors bind to the RANK 
receptor, promoting osteoclast differentiation and proliferation. OPG acts 
as a decoy receptor to block the action of RANKL. This system provides 
a balance between bone formation and resorption and through which a 
wide variety of biological mediators such as hormones, cytokines, and 
growth factors affect bone homeostasis. RANKL enhances osteoclastic 
function that elevated in β-TM patients, while OPG and OPG/RANKL ratio 
reduced, associated with low bone mineral density (BMD), this gives 
evidence that OPG/RANKL system plays a key role in the pathogenesis of 
osteoporosis in β-TM [10,11].
Ineffective erythropoiesis results in erythroid hyperplasia and marrow 
expansion secondary to extramedullary hematopoiesis [6], resulting in 
expansion of the medulla, thinning of cortical bone and resorption of 
cancellous bone causing a generalized loss of BMD [11]. Deposition of 
iron in the bones impairs osteoid maturation and inhibits mineralization 
locally; this occurs by a mechanism that includes the incorporation of 
iron into calcium hydroxyapatite crystals which consequently affects 
their growth [12]. Deferoxamine (DFO) is an iron chelator used to 
reduce iron overload in patients with thalassemia, but on the other 
hand, it was found to have harmful effects on bone status. It exerts a 
direct effect by interfering with bone growth and by altering bone 
metabolism due to chelation of trace metals. DFO exerts deleterious 
effects on osteoblasts through inhibition of deoxyribonucleic acid 
(DNA) synthesis, osteoblasts proliferation, and differentiation of 
osteoblastic precursors and in patients receiving high doses it enhances 
osteoblasts apoptosis [13,14].
Parathyroid hormone (PTH) secreted by the parathyroid gland and 
functions in calcium homeostasis together with Vitamin D and calcitonin, 
PTH maintains calcium levels within normal range by facilitating its 
absorption from the gastrointestinal tract, by phosphorous excretion 
and calcium reabsorption from the kidney, and by bone resorption. PTH 
also plays a role in the conversion of Vitamin D to its active form (1, 
25-dihydroxycholecalciferol) in the kidneys [15].
Iron deposition within the parathyroid gland occurs in patients 
with iron overload due to recurrent transfusions and results in 
hypoparathyroidism (HPT), particularly after 10 years of age, as 
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a consequence of that low PTH and Vitamin D ensued. HPT is also a 
leading cause of hypocalcemia, and several neurological complications 
may evolve such as tetany, seizures, and paresthesia [16,17].
METHODS
Patient selection and study design
The present study designed as a single-center, cross-sectional, 
observational study. The study performed at AL-Karama Teaching 
Hospital/Department of Hereditary Blood Disorders (Thalassemia 
Center). The participant patients in this study were all with β-TM trait who 
were attending Thalassemia Centre at Al-Karama Hospital for recurrent 
blood transfusion and for receiving their iron chelation therapy. A total 
of 201 patients approved to enroll in the study, written informed consent 
taken from all patients (and for underaged patients the written informed 
consent also taken from their legal guardian). The patients divided into 
two main groups: Group A: Patients on DFO are subdivided into two 
groups: Children and adolescents (8–18 years) and adults (19 and more) 
and Group B: Patients on deferasirox (DFX) are subdivided into two 
groups: Children and adolescents (8–18 years) and adults (19 and more).
The sample size calculated using Raosoft sample calculator (online tool), a 
total of 600 patients with β-TM were registered at AL-Karama Thalassemia 
Centre; hence, a sample size of approximately 200 patients should be 
included assuming a margin of error of 5% and a confidence level of 95%.
Method of bone status evaluation
About 5 ml of fasting pre-transfusional venous blood collected and 
serum stored at −20°C after separation. Serum ferritin (SF) level was 
measured using Cobas e 411 (Roche diagnostic equipment). The ELISA 
kits were used to determine serum levels of calcium and 25-OH Vitamin 
D. Immunoenzymatic assay used for the evaluation of PTH. Dual-energy 
X-ray absorptiometry (DEXA) scan of the lumbar spine region done as 
an index of bone density. BMD is expressed in grams of minerals per 
scanned square centimeters (g/cm2) and interpreted in relationship to 
Z-score which compares to the BMD of age, sex, and ethnicity of the 
matched reference population [18,19]. In the assessment of the lumbar 
spine, the region of interests placed on the L1-L4 vertebral bodies [20]. 
Patients with Z-score of -1SD or greater are considered normal, Z-scores 
between −1 and −2.5 are osteopenic (low bone mass), Z-scores of −2.5 
or less are considered osteoporotic, and severely osteoporotic patients 
are those having Z-score of <−2.5 with fragility fracture [21].
Statistical analysis
Discrete variables presented using their numbers and percentages; Chi-
square test was used to analyze the discrete variables (or Fisher exact test 
when Chi-square test is not valid; due to low sample size ˂20 and if two 
or more with an expected frequency is <5). Two samples t-test was used 
to analyze the differences in means between two groups (if both follow a 
normal distribution with no significant outlier). Binary logistic regression 
analysis was used to calculate the odds ratio and their 95% confidence 
intervals when the outcome can categorize into two binary levels, and 
if appropriate probability plot used to present the relationship. Linear 
regression analysis was performed to assess the relationship between 
different variables. If one or both of the variables were following a normal 
distribution, Pearson correlation is used. If both did not follow a normal 
distribution, the Spearman correlation used. Scatter plot was used to 
present the regression analysis. Correlation coefficient or standardized 
beta (r) is a representative of magnitude and direction of the relationship; 
0.00–0.29=little or no correlation; 0.3–0.49=weak; 0.5–0.69=moderate; 
0.7–0.89=strong; and 0.9–1.00=very strong. The negative sign indicates an 
inverse relationship, while a positive sign indicates a direct relationship. 
Statistics is a Software Package 22 (Chicago, IL), Minitab 17.1.0 software 
package was used to make the statistical analysis, p-value considered to 
be statistically significant if <0.05.
RESULTS
The demographic data and disease characteristics illustrated in Table 1; 
a total of 201 patients were approved to include in the study. In this 
study, the patients included fall into three groups: Children (8–12), 
n=40; (19.9%), adolescents (13–18), n=78; (38.8%), and adults (˃19), 
n=83; (41.3%), but children and adolescents were considered as a one 
category (pediatric) during the study. The frequency of their attendance 
was every 2 weeks, and their age of onset on blood transfusion was 
approximately 13.7±9.0 months.
Although there is no statistical difference in SF between pediatrics and 
adults, 66 patients were having their SF between 1000 and 2500 ng/ml 
and 122 patients with SF ˃2500. Calcium and Vitamin D levels are low 
in both adults and pediatrics. The bone status shows high percentages 
of osteoporosis 62% and 54.5% for both pediatrics and adults, 
respectively, as well as osteopenia 27% and 34.3% for both pediatrics 
and adults and to a lesser extent normal bone status 11% for each as 
illustrated in Tables 2 and 3.
Advanced age predicts a decrease in BMD and osteoporosis 
insignificantly. However, males having higher BMD in comparison 
to females; there was no significant effect on BMD. DFX inversely 
associated with osteoporosis as illustrated in Table 4. Increase in iron 
overload predicts osteoporosis, but the relationship is insignificant.
In univariate analysis advance age, DFO and elevated ferritin predict 
osteoporosis (Table 5).
There was no significant correlation between the different variable in 
Table 6 with osteoporosis in the adult.
DISCUSSION
Osteopathy affects 40–50% of the patients with thalassemia major. 
The mechanism of osteopathy in β-TM is multifactorial and comprises 
the effects of anemia on bone health, secondary to iron deposition 
Table 1: Demographic data and disease characteristics
Variables Value
Number 201
Age (years), mean±SD 19.1±7.3
8–12 years 40 (19.9%)
13–18 years 78 (38.8%)




BMI (kg/m2), mean±SD 21.4±4.0
The frequency of attendance (days), mean±SD 14.7±4.3
Age at which disease diagnosed (months), mean±SD 13.7±9.0
SD: Standard deviation
Table 2: Assessment of bone status and various biochemical 
parameters
Variables Paediatrics* Adults p-value
Number 100 101 -
Ferritin (ng/mL) 3,957.9±2,914.0 3,761.7±2,452.9 0.606
<1000 7 (7.0%) 6 (5.9%) 0.737
1000–2500 35 (35.0%) 31 (30.7%)
>2500 58 (58.0%) 64 (63.4%)
Calcium (mmol/L) 2.06±0.23 2.1±0.2 0.227
Vitamin D (ng/mL) 10.5±8.5 11.4±9.1 0.498
PTH (pg/mL) 35.7±27.1 34.0±23.4 0.644
Z score −2.7±1.4 −2.5±1.2 0.186
Bone status
Normal (˃1 SD) 11 (11.0%) 11 (11.1%) 0.509
Osteopenia  
(−1)–(−2.5 SD)
27 (27.0%) 34 (34.3%)
Osteoporosis  
(˂−2.5 SD)
62 (62.0%) 54 (54.5%)
*Pediatrics (children and adolescents). PTH: Parathyroid hormone
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(hemosiderosis) of various endocrine glands, liver dysfunction, chronic 
illness affecting physical health, and chelation therapy inducing toxicity. 
Recently, the receptor activator of nuclear ƙB (RANK)/RANK ligand 
and OPG system has been found to be the dominant pathway affecting 
osteoclastic activation and proliferation and plays a major role in 
thalassemia-induced osteoporosis [22,23].
DEXA is a non-invasive method for the assessment of BMD; in the 
present study, the osteopenia was in 27% of pediatrics and 34.3% 
of adults (totally 30.35%), while osteoporosis was 62% in pediatrics 
and 54.5% in adults (totally 57.7%), and the total normal BMD was in 
only 10.9%. The results of the Z score in our study were comparable 
to Valizadeh et al. [19] and Merchant et al. [24]. Our findings state 
that there is no significant difference in Z score between adults and 
pediatrics which appears to be in sharp contrast to Mohseni et al. [25], 
in which they concluded that low BMD in pediatrics is less common 
than adults. However, in our study, there was a non-significant direct 
relationship between advancing in age and decrease in BMD and 
osteoporosis this was in agreement with AL-Amir et al. [26]; however, 
in pediatrics advance in age significantly (in univariate analysis) and 
dependently (in multivariate analysis) predict osteoporosis which 
is in agreement with Merchant et al. [24] and Izadyar et al. [27] who 
reported a statistically significant relationship between age and BMD; 
nevertheless, Izadyar et al. have the same findings regarding gender 
in which both of us found no significant association between gender 
and BMD, and our finding regarding gender was in disagreement with 
Mohseni et al., who reported a significant effect of gender on BMD in 
which males had higher BMD, but their findings undermined because of 
its ineffectiveness on Z score [25].
The effect of splenectomy on BMD was not significant (p=0.06) which 
was in agreement with Merchant et al. [24] up to our knowledge, the 
effect of splenectomy on BMD was not studied more often. In adults, 
the increase in SF predicts insignificantly (p=0.544) osteoporosis 
while in pediatrics SF is a dependent and significant predictor of 
osteoporosis, this was consistent with a study conducted on 70 children 
and adolescents by Nesheli and Farahanian [28] which reported a 
significant relationship between SF and bone density. The lack of 
significant correlation between SF and BMD in adults could attribute 
to SF tolerance, SF measurements may vary at different times, and 
other possibilities are small sample size, measurements error, and 
type of chelator used. The mechanism of iron toxicity on the bone is 
elucidated by its local effect which impairs osteoid maturation and 
bone mineralization which occurs by iron incorporation into calcium 
hydroxyapatite crystals which are important information of normal 
bones in which these crystals deposited on a proteinaceous collagen 
matrix [12].
DFO is considered a significant predictor for osteopathy, osteopenia and 
osteoporosis were higher in patients using DFO, and this could attribute 
to low compliance with DFO and high SF levels in these patients. DFO 
exerts a deleterious effect on bone through its direct effect by altering 
bone metabolism by chelating trace metals. DFO affects osteoblasts 
through inhibition of DNA synthesis, osteoblasts proliferation, and 
differentiation of osteoblastic precursors and in patients receiving high 
doses it enhances osteoblasts apoptosis [13].
The reason behinds low BMD and high prevalence of osteoporosis in 
both populations in the present study attributed to high SF levels, low 
calcium and Vitamin D levels, poor nutritional supports, limited physical 
activity, and inappropriate chelation. The impaired calcium hemostasis 
is thought to be a consequence of iron overload, Vitamin D deficiency, 
and HPT [29]. According to Shah study [30], hypocalcemia in states 
of iron overload is usually chronic and asymptomatic. Hypocalcemia 
(resulting from HPT) occurs through increasing calcium loss through 
urine and decrease intestinal absorption of calcium. The reported 
calcium levels in Salva’s study were comparable to our levels.
The PTH levels in this study were various range from 8.6 to 62.8 pg/ml 
in pediatrics and from 10.6 to 57.4 in adults, the PTH levels in our study 
are comparable to many studies [26,31]. The development of HPT is 
mainly considered a consequence of iron overload, Pirinççioğlu and 
Söker [31] found a positive correlation between SF levels and PTH, 
while  Chern and Lin [32] found that the development of HPT is not 
correlated with SF as many patients developed HPT while their SF 
Table 3: SF levels and bone status among patients using DFO and 
DFX
Variables DFO DFX p-value
Number 99 102 -
Ferritin 5028.8±3006.5 2724.1±1699.2 <0.001 [S.]
<1000 3 (3.0%) 10 (9.8%) <0.001 [S.]
1000–2500 19 (19.2%) 47 (46.1%)
>2500 77 (77.8%) 45 (44.1%)
Z score −2.8±1.2 −2.4±1.4 0.014 [S.]
Bone status
Normal 5 (5.1%) 17 (16.8%) 0.009 [S.]
Osteopenia 27 (27.6%) 34 (33.7%)
Osteoporosis 66 (67.3%) 50 (49.5%)
DFO: Deferoxamine, DFX: Deferasirox
Table 4: Predictors of osteoporosis for all patients 
Variables Osteoporosis
OR (95% CI) p-value
Age 1.009 (0.971−1049) 0.647
Gender 1.420 (0.805−2.504) 0.226
BMI 0.960 (0.894−1.030) 0.253
Treatment (DFX) 0.475 (0.268−0.845) 0.011 [S.]
Splenectomy 2.083 (0.970−4.470) 0.060
Ferritin 1.000 (1.000−1.000) 0.149
Calcium 0.102 (0.964−1.260) 0.156
Vitamin D 0.974 (0.943−1.006) 0.113
PTH 1.010 (0.998−1.023) 0.109
OR: Odds ratio, CI: Confidence interval, BMI: Body mass index, PTH: Parathyroid 
hormone, DFX: Deferasirox
Table 5: Predictors of osteoporosis for pediatric patients
Variables Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Age 1.169 (1.034−1.320) 0.012 [S.] 1.090 (0.919−1.293) 0.31
Gender 1.111 (0.495−2.493) 0.798 - -
BMI 0.959 (0.870−1.057) 0.398 - -
Treatment (DFX) 0.333 (0.142−0.780) 0.011 [S.] 0.576 (0.133−2.505) 0.462
Ferritin 1.000 (1.000−1.000) 0.022 [S.] 1.000 (1.000−1.000) 0.459
Calcium 1.091 (0.943−1.262) 0.240 - -
Vitamin D 0.987 (0.941−1.035) 0.581 - -
PTH 1.011 (0.993−1.030) 0.217 - -
R2 (Cox and Snell)=0.282, PTH: Parathyroid hormone, BMI: body mass index, DFX: Deferasirox, OR: Odds ratio, CI: Confidence interval
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levels were lower than other patients. HPT development in their study 
was found to be dependent on patients’ related factors and tendencies. 
Several mechanisms were postulated to describe the glandular damage 
by iron overload which mainly occurs in the second or third decade of 
life: 1 - the formation of free radicals and lipid peroxidation causing 
mitochondrial, lysosomal, and sarcolemmal membrane damage, 
2 - number of surface transferrin receptors in the cell, and 3 - the ability 
of the cell to protect itself against iron species [31,33].
Vitamin D is crucial for calcium and phosphorous absorption. Vitamin 
D has a direct relation to BMD, and maximum BMD achieved when the 
25-OH-D level is 40 ng/ml or more [34]. In our study, serum Vitamin D 
levels are apparently deficient in both pediatrics and adults (10.5±8.5 in 
pediatrics and 11.4±9.1 in adults) which are comparable to Akhouri and 
Neha [35] and Merchant et al. [24] Vitamin D deficiency in patients with 
β-TM attributed to nutritional deficiency and hepatic impairment due to 
hemosiderosis which results in defective hydroxylation of Vitamin D to 
25-OH-Vitamin D, levels of Vitamin D ˃30 ng/ml is considered normal 
and levels between 10-20 ng/ml are considered deficient and levels of 
21–29 ng/ml is considered insufficient [24,34].
CONCLUSION
Osteopathy (osteopenia and osteoporosis) has a high prevalence in 
Iraqi patients with β-TM. Poor chelation, undernourishment, calcium 
and Vitamin D deficiency, and secondary HPT are the leading cause 
of osteopathy. Therapeutic intervention should initiate in the case of 
Vitamin D and calcium deficiency. Annual BMD evaluation is crucial to 
avoid osteopathy in thalassemia patients in Iraq.
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